TherapeuticsMD Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices rise 2% as US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
TherapeuticsMD (TXMD) PT Lowered to $5 at Stifel
May 6, 2021 2:00 PM EDTStifel analyst Annabel Samimy lowered the price target on TherapeuticsMD (NASDAQ: TXMD) to $5.00 (from $6.00) while maintaining a Buy rating.
The analyst commented, "While investor worry remained at a peak, TXMD posted sales of $19.9mn/Cons $19,8mn, with FDA-product sales of $18.3mn coming... More
TherapeuticsMD (TXMD) Tops Q1 EPS by 1c, Revenues Beat
May 6, 2021 7:11 AM EDTTherapeuticsMD (NASDAQ: TXMD) reported Q1 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $19.9 million versus the consensus estimate of $19.77 million.
I am pleased with our ongoing execution across the organization, which is in-line with our 2021... More
